F Couñago1, G Sancho2, A Gómez-Iturriaga3, I Henríquez4. 1. Department of Radiation Oncology, Hospital Universitario Quirónsalud, Madrid, Universidad Europea de Madrid, Calle Diego de Velázquez, 2, Pozuelo de Alarcón, 28223, Madrid, Spain. felipe.counago@quironsalud.es. 2. Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Department of Radiation Oncology, Hospital Universitario Cruces, Biocruces Health Research Institute, Barakaldo, Spain. 4. Department of Radiation Oncology, Hospital Universitario de Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Spain.
Abstract
PURPOSE: To investigate patterns of practice among Spanish radiation oncologists in the use of multiparametric magnetic resonance imaging (mpMRI) for the treatment of prostate cancer (PCa). We evaluated (1) access to mpMRI, (2) current clinical practices, and (3) physician expectations of mpMRI. METHODS: Cross-sectional survey of 118 radiation oncologists at 75 Radiation Oncology (RO) departments in Spain. RESULTS: A total of 55 radiation oncologists from 52 RO departments (52/75; 69%) completed the survey. Prostate mpMRI is performed at 94.5% of the centres that provided data. The most common indications for mpMRI in routine clinical practice were: (1) detection/localization of the tumour prior to second biopsy (82.7%), (2) cancer staging (80.8%), and (3) detection of recurrence after definitive treatment (80.8%). Most respondents (72.7%) reported modifying the primary radiotherapy treatment when mpMRI findings indicate a more advanced T stage with a resultant change in the risk group. Most respondents (90.5%) treat macroscopic local recurrence after prostatectomy with high doses, ranging from 71 to 83 Gy; in 37.7% of cases, the full dose is delivered to the entire prostate bed. In pelvic nodal recurrence, more than half (59.3%) of the respondents reported performing elective pelvic radiotherapy, including the prostate bed, with a boost to the involved nodes. CONCLUSIONS: This survey shows that prostate mpMRI is routinely used by radiation oncologists in Spain in a wide range of clinical scenarios. The findings reported here underscore the need to standardize treatment protocols for definitive and salvage radiotherapy in patients evaluated with mpMRI.
PURPOSE: To investigate patterns of practice among Spanish radiation oncologists in the use of multiparametric magnetic resonance imaging (mpMRI) for the treatment of prostate cancer (PCa). We evaluated (1) access to mpMRI, (2) current clinical practices, and (3) physician expectations of mpMRI. METHODS: Cross-sectional survey of 118 radiation oncologists at 75 Radiation Oncology (RO) departments in Spain. RESULTS: A total of 55 radiation oncologists from 52 RO departments (52/75; 69%) completed the survey. Prostate mpMRI is performed at 94.5% of the centres that provided data. The most common indications for mpMRI in routine clinical practice were: (1) detection/localization of the tumour prior to second biopsy (82.7%), (2) cancer staging (80.8%), and (3) detection of recurrence after definitive treatment (80.8%). Most respondents (72.7%) reported modifying the primary radiotherapy treatment when mpMRI findings indicate a more advanced T stage with a resultant change in the risk group. Most respondents (90.5%) treat macroscopic local recurrence after prostatectomy with high doses, ranging from 71 to 83 Gy; in 37.7% of cases, the full dose is delivered to the entire prostate bed. In pelvic nodal recurrence, more than half (59.3%) of the respondents reported performing elective pelvic radiotherapy, including the prostate bed, with a boost to the involved nodes. CONCLUSIONS: This survey shows that prostate mpMRI is routinely used by radiation oncologists in Spain in a wide range of clinical scenarios. The findings reported here underscore the need to standardize treatment protocols for definitive and salvage radiotherapy in patients evaluated with mpMRI.
Entities:
Keywords:
Magnetic resonance imaging; Prostate cancer; Radiation oncologists; Survey
Authors: Daniel E Spratt; Robert T Dess; Zachary S Zumsteg; Daniel W Lin; Phuoc T Tran; Todd M Morgan; Emmanuel S Antonarakis; Paul L Nguyen; Charles J Ryan; Howard M Sandler; Matthew R Cooperberg; Edwin Posadas; Felix Y Feng Journal: Eur Urol Date: 2017-07-14 Impact factor: 20.096
Authors: William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Jihong Wang; Kari Tanderup; Adam Cunha; Antonio L Damato; Gil'ad N Cohen; Rajat J Kudchadker; Firas Mourtada Journal: Brachytherapy Date: 2017-04-07 Impact factor: 2.362
Authors: Alfonso Gomez-Iturriaga; Francisco Casquero; Jose Ignacio Pijoan; Juanita Crook; Arantza Urresola; Ana Ezquerro; Geert M Villeirs; Alberto Bossi; Jon Cacicedo; David Buchser; Pedro Bilbao Journal: Int J Radiat Oncol Biol Phys Date: 2018-04-22 Impact factor: 7.038
Authors: Jehonathan H Pinthus; Maciej Witkos; N E Fleshner; Joan Sweet; Andrew Evans; M A Jewett; Murray Krahn; Shabir Alibhai; John Trachtenberg Journal: J Urol Date: 2006-09 Impact factor: 7.450
Authors: Ivo G Schoots; Monique J Roobol; Daan Nieboer; Chris H Bangma; Ewout W Steyerberg; M G Myriam Hunink Journal: Eur Urol Date: 2014-12-03 Impact factor: 20.096
Authors: R Renard-Penna; O Rouvière; P Puech; C Borgogno; L Abbas; C Roy; M Claudon; J-M Correas; L Cormier; G Ploussard; A Mejean; S Tezenas-du-Montcel; F Rozet Journal: Diagn Interv Imaging Date: 2016-07-20 Impact factor: 4.026
Authors: Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro Journal: World J Clin Oncol Date: 2017-08-10
Authors: Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro Journal: Rep Pract Oncol Radiother Date: 2019-08-08